Immutep (IMMP) News Today → Don’t Miss Out on the AI Gold Rush That’s Just Getting Started (From Banyan Hill Publishing) (Ad) Free IMMP Stock Alerts $2.32 +0.07 (+3.11%) (As of 04/22/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMutual Fund Series Trust - Alphacentric Municipal Opportunities Fund (MUNIX)finance.yahoo.com - April 19 at 10:35 AMImmutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761globenewswire.com - April 18 at 8:00 AMImmutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancerglobenewswire.com - April 17 at 8:00 AMImmutep Limited (NASDAQ:IMMP) Sees Large Growth in Short Interestamericanbankingnews.com - April 16 at 5:34 AMImmutep Limited (NASDAQ:IMMP) Short Interest Up 10.5% in Marchmarketbeat.com - April 15 at 7:19 AMImmutep (NASDAQ:IMMP) Stock Crosses Above 50 Day Moving Average of $2.35marketbeat.com - March 9 at 4:53 AMImmutep Ltd Sponsored ADRedition.cnn.com - March 7 at 8:49 PMImmutep Limited (NASDAQ:IMMP) Holdings Cut by Oracle Investment Management Inc.marketbeat.com - March 1 at 11:48 AMImmutep (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average of $2.33marketbeat.com - February 23 at 5:36 AMImmutep (NASDAQ:IMMP) Share Price Crosses Below Fifty Day Moving Average of $2.25marketbeat.com - February 2 at 5:08 AMBuy Rating Affirmed for Immutep on Strong Clinical Pipeline and Market Potentialmarkets.businessinsider.com - February 1 at 8:43 AMImmutep Limited (NASDAQ:IMMP) Short Interest Updatemarketbeat.com - January 15 at 2:56 AMImmutep Limited (NASDAQ:IMMP) Sees Large Increase in Short Interestmarketbeat.com - January 13 at 10:19 AMFirst Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancerfinance.yahoo.com - January 4 at 9:50 AMImmutep: Upcoming Signals For 2024 (Maintain Buy)seekingalpha.com - January 3 at 6:58 PMMeridian Wealth Management LLC Purchases 48,150 Shares of Immutep Limited (NASDAQ:IMMP)marketbeat.com - December 28 at 6:01 AMImmutep Limited (IMMP)finance.yahoo.com - December 24 at 12:10 AMImmutep Limited (NASDAQ:IMMP) Sees Significant Decline in Short Interestmarketbeat.com - December 17 at 8:40 AMImmutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancerfinance.yahoo.com - November 6 at 9:16 AMImmutep Limited: Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancerfinanznachrichten.de - November 3 at 2:23 PMImmutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancermarkets.businessinsider.com - November 3 at 2:23 PMImmutep to Participate in November Investor Eventsfinance.yahoo.com - November 2 at 8:57 AMBuy Rating for Immutep (IMMP) Supported by Strong Phase 2 Study Results and Solid Financial Positionmarkets.businessinsider.com - October 27 at 12:51 AMImmutep receives about A$1.13M R&D tax incentive from Australian govtmsn.com - October 25 at 1:31 PMImmutep receives ~A$1.13 million R&D Tax Incentivefinance.yahoo.com - October 25 at 8:30 AMImmutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023finance.yahoo.com - October 24 at 9:30 AMImmutep's Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancerstockhouse.com - October 23 at 8:37 AMImmutep : Efti+ Keytruda Generates Excellent OS Benefit In Phase II Trial In Metastatic NSCLCmarkets.businessinsider.com - October 22 at 11:52 PMImmutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meetingfinance.yahoo.com - October 3 at 10:38 AMImmutep to Participate in September Investor Conferencesfinance.yahoo.com - September 5 at 3:55 PMRobert W. Baird Reaffirms Their Buy Rating on Immutep (IMMP)markets.businessinsider.com - August 30 at 2:36 AMImmutep Limited - ADR (IMMP) Price Target Increased by 21.21% to 2.84msn.com - August 3 at 6:17 AMImmutep Receives Positive Scientific Advice from European Medicines Agencyfinance.yahoo.com - August 1 at 3:38 PMImmutep Granted United States Patent for IMP761, a First-in-Class Agonist Antibody Targeting LAG-3finance.yahoo.com - June 20 at 8:19 AMImmutep Reports Final Positive Data in 2nd Line Head and Neck Squamous Cell Carcinoma at ASCO 2023 Annual Meetingbenzinga.com - June 5 at 9:39 AMIMMP - Immutep Limitedau.finance.yahoo.com - June 3 at 7:24 PMImmutep Successfully Completes Institutional Placement and Institutional Component of its Entitlement Offerfinance.yahoo.com - June 2 at 8:20 AMmarketbeat.com - May 31 at 6:12 AMMaxim Group Maintains Buy Rating for Immutep: Here's What You Need To Knowmsn.com - May 18 at 4:58 PMImmutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Datafinance.yahoo.com - May 18 at 4:58 PMImmutep Soars with New Cancer Treatmentmsn.com - May 17 at 5:55 PMImmutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trialmsn.com - May 17 at 12:49 PMImmutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancerfinance.yahoo.com - May 16 at 8:16 AMImmutep Announces KOL Event Focused on Eftilagimod Alpha in Non-Small Cell Lung Cancer and Head & Neck Squamous Cell Carcinomafinance.yahoo.com - May 2 at 8:40 AMImmutep Announces Presentation of New TACTI-002 Data at the 2023 ASCO Annual Meetingfinance.yahoo.com - April 26 at 10:48 AMWhy Did Immutep Ltd Stock Soar Recently?marketbeat.com - December 28 at 2:00 AMImmutep Announces Promising Initial Clinical Data from INSIGHT-003 at SITC 2022finance.yahoo.com - November 10 at 5:23 PMImmutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combinationfinance.yahoo.com - November 9 at 11:43 AMImmutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conferencefinance.yahoo.com - November 4 at 8:11 AMShort Interest in Immutep Limited (NASDAQ:IMMP) Rises By 34.4%marketbeat.com - October 15 at 7:04 AM Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry IMMP Media Mentions By Week IMMP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMMP News Sentiment▼0.760.47▲Average Medical News Sentiment IMMP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMMP Articles This Week▼40▲IMMP Articles Average Week Get Immutep News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Merrimack Pharmaceuticals News Acrivon Therapeutics News Theseus Pharmaceuticals News ProQR Therapeutics News NGM Biopharmaceuticals News Kinnate Biopharma News Assembly Biosciences News vTv Therapeutics News BeyondSpring News AVROBIO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMMP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immutep Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
